Mike Dixon

Mike Dixon joined Transformation Capital in 2019 after more than a decade as a partner at Sequoia Capital, where he worked alongside Todd Cozzens for several years.

Mike currently serves on the board of Health Catalyst (ticker: HCAT), Implantable Provider Group, and Clover Health. Previously, he served on the boards of Trialspark, Cortexyme (observer position, ticker: CRTX), Airstrip Technologies, Endochoice (acquired by Boston Scientific), and Percolate, a marketing software-as-a-service company (acquired by Seismic). He also led or co-led additional healthcare investments in MedExpress (acquired by UnitedHealth Group), Stemcentrx (acquired by Abbvie), 23andMe, and BridgeBio (ticker: BBIO).

Prior to his time at Sequoia Capital, Mike was an Equity Research Associate at Fidelity Management & Research Company. He graduated summa cum laude from Boston College in 2006 and was a member of the Presidential Scholars Program. He lives in San Francisco with his wife and three boys.